Advanced research and perspectives on the future of bioconjugation.
Therapeutic success hinges on a complex challenge: only 1-2% of delivered drugs successfully reach their target within the cell. Addressing this bottleneck is critical for the next generation of molecular medicines.
Read Article
Utilizing the ASGPR receptor to achieve precise biological targeting. GalNAc remains the benchmark for hepatocyte-directed oligonucleotide therapeutics and future delivery platforms.
Read Article
The trajectory of ADC technology is shifting from chemistry-first to a biology-first approach, overcoming complexities inherent to tumor microenvironments and antigen density.
Read Article